Despite its popularity, the Traditional Chinese Medicine (TCM) Market faces a significant "validation gap." Western regulators often demand placebo-controlled, Phase III clinical trials—a process that is prohibitively expensive for many traditional manufacturers. This hurdle can restrain the market by up to 1.1% of its potential CAGR in high-import regions like North America and the EU,...